Effect of everolimus on cell viability in nonfunctioning pituitary adenomas

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 2, 2010, Pages 968-976

  Zatelli, Maria Chiara ^a   Minoia, Mariella ^a   Filieri, Carlo ^a   Tagliati, Federico ^a   Buratto, Mattia ^a   Ambrosio, Maria Rosaria ^a   Lapparelli, Marcello ^b   Scanarini, Massimo ^c   Degli Uberti, Ettore C ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE 2 RECEPTOR; EVEROLIMUS; PASIREOTIDE; S6 KINASE; SOMATOMEDIN C; SOMATOSTATIN; VASCULOTROPIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 76149106804     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1641     Document Type: Article

References (34)

1. Katznelson L, Alexander JM, Klibanski A 1993 Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 76:1089-1094
2. Ferrante E, Ferraroni M, Castrignanò T, Menicatti L, Anagni M, Reimondo G, Del Monte P, Bernasconi D, Loli P, Faustini-Fustini M, Borretta G, Terzolo M, Losa M, Morabito A, Spada A, Beck-Peccoz P, Lania AG 2006 Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumours. Eur J Endocrinol 155:823-829
3. Jaffe CA 2006 Clinically non-functioning pituitary adenoma. Pituitary 9:317-321
4. Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S 2008 Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer 15:905-915
5. Molitch ME 2008 Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am 37:151-171
6. Boelaert K, Gittoes NJ 2001 Radiotherapy for nonfunctioning pituitary adenomas. Eur J Endocrinol 144:569-575
7. Gittoes NJ 2003 Radiotherapy for non-functioning pituitary tumours - when and under what circumstances? Pituitary 6:103-108
8. Florio T, Barbieri F, Spaziante R, Zona G, Hofland LJ, van Koetsveld PM, Feelders RA, Stalla GK, Theodoropoulou M, Culler MD, Dong J, Taylor JE, Moreau JP, Saveanu A, Gunz G, Dufour H, Jaquet P 2008 Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human nonfunctioning pituitary adenomas: a multi-center study. Endocr Relat Cancer 15:583-596
9. Greenman Y 2007 Dopaminergic treatment of nonfunctioning pituitary adenomas. Nat Clin Pract Endocrinol Metab 3:554-555
10. Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P, Colao A, Annunziato L, Lombardi G 2004 Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 89:1674-1683
11. Greenman Y, Tordjman K, Osher E, Veshchev I, Shenkerman G, Reider-Groswasser II, Segev Y, Ouaknine G, Stern N 2005 Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin Endocrinol (Oxf) 63:39-44
12. Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson 3rd AB, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan Jr RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y 2008 NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw 6:S1-S20
13. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F 2008 Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26:4311-4318
14. Böhm A, Aichberger KJ, Mayerhofer M, Herrmann H, Florian S, Krauth MT, Derdak S, Samorapoompichit P, Sonneck K, Vales A, Gleixner KV, Pickl WF, Sperr WR, Valent P 2009 Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells. Eur J Clin Invest 39: 395-405
15. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ 2002 Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238-4244
16. Yamada S, Takada K 2003 Angiogenesis in pituitary adenomas. Microsc Res Tech 60:236-243
17. Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC 2007 Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 14:91-102
18. Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla G, Cohen Z, Hadani M, Shimon I 2009 mTOR inhibitors rapamycin and RAD001 (Everolimus) induce antiproliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer 16:1017-1027
19. Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzini L, degli Uberti EC 2004 Evidence for differential effects of selective somatostatin receptor subtypeagonistson α-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. J Clin Endocrinol Metab 89:5181-5188
20. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716
21. Chanson P, Brochier S 2005 Non-functioning pituitary adenomas. J Endocrinol Invest 28:93-99
22. Andersen M, Bjerre P, Schrøder HD, Edal A, Høilund- Carlsen PF, Pedersen PH, Hagen C 2001 In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clin Endocrinol (Oxf) 54:23-30
23. Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, degli Uberti EC 2001 Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT. J Clin Endocrinol Metab 86:2161-2169
24. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A, Vignali C, Margutti A, Bondanelli M, Pansini GC, Pelizzo MR, Culler MD, Degli Uberti EC 2006 Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. J Clin Endocrinol Metab 91:2218-2224
25. Chelly J, Concordet JP, Kaplan JC, Kahn A 1989 Illegitimate transcription: transcription of any gene in any cell type. Proc Nat Acad Sci USA 86:2617-2621
26. Kenerson H, Dundon TA, Yeung RS 2005 Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res 57: 67-75
27. Niiori-Onishi A, Iwasaki Y, Mutsuga N, Oiso Y, Inoue K, Saito H 1999 Molecular mechanisms of the negative effect of insulin-like growth factor-I on growth hormone gene expression in MtT/S somatotroph cells. Endocrinology 140:344-349
28. Soldani R, Cagnacci A, Yen SS 1994 Insulin, insulin-like growth factor I (IGF-I) and IGF-II enhance basal and gonadotrophin-releasing hormone-stimulated luteinizing hormone release from rat anterior pituitary cells in vitro. Eur J Endocrinol 131:641-645
29. Tondolo V, Citterio F, Panocchia N, Nanni G, Favi E, Brescia A, Castagneto M 2005 Gonadal function and immunosuppressive therapy after renal transplantation. Transplant Proc 37:1915-1917
30. Kaczmarek I, Groetzner J, Adamidis I, Landwehr P, Mueller M, Vogeser M, Gerstorfer M, Uberfuhr P, Meiser B, Reichart B 2004 Sirolimus impairs gonadal function in heart transplant recipients. Am J Transplant 4:1084-1088
31. Cristina C, Diaz-Torga G, Baldi A, Góngora A, Rubinstein M, Low MJ, Becú-Villalobos D 2005 Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice. Endocrinology 146:2952-2962
32. Ferone D, Gatto F, Arvigo M, Resmini E, Boschetti M, Teti C, Esposito D, Minuto F 2009 The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol 42:361-370
33. Neto LV, Machado Ede O, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, Quintella LP, Niemeyer Jr P, de Carvalho DP, Kineman RD, Gadelha MR 2009 Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab 94:1931-1937
34. Durán-Prado M, Gahete MD, Martínez-Fuentes AJ, Luque RM, Quintero A, Webb SM, Benito-López P, Leal A, Schulz S, Gracia-Navarro F, Malagón MM, Castaño JP 2009 Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab 94:2634-2643